On July 1, 2026, Viatris Inc. entered into an amended and restated term loan credit agreement with Mizuho Bank, Ltd. as administrative agent. The agreement establishes a ¥40,000,000,000 senior unsecured term loan facility to be used for general corporate purposes and to repay an existing ¥40,000,000,000 unsecured term loan facility from 2021. The facility carries an initial interest rate of the TIBO Rate plus 1.10% per annum, with a leverage ratio covenant not to exceed 3.75 to 1.00. The loan is due three years from the closing date. Viatris is a global healthcare company that develops and distributes generic and branded medicines.

Viatris Inc. completed a public offering of €650,000,000 in 4.250% Senior Notes due 2033 on June 17, 2026. The senior unsecured notes are guaranteed by Mylan Inc., Mylan II B.V., and Utah Acquisition Sub Inc. Net proceeds are intended to fund the repayment of the company's $1.675 billion 3.950% Senior Notes due 2026 and to replenish cash for general corporate purposes. The notes carry an annual interest rate of 4.250% and mature on June 17, 2033. Viatris is a global healthcare company that develops and manufactures generic and branded pharmaceutical products.

Viatris Inc. entered into an underwriting agreement on June 12, 2026, to issue and sell €650,000,000 principal amount of 4.250% Senior Notes due 2033. BNP Paribas, Citigroup Global Markets Limited, and Goldman Sachs & Co. LLC are acting as representatives for the underwriters. The offering is expected to close on June 17, 2026. Viatris Inc. is a global healthcare company that develops and manufactures generic and branded pharmaceutical products.